UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-QSB

(Mark One)
[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2006

[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT
For the transition period from __________ to __________

COMMISSION FILE NUMBER: **000-31469**

MEDICAL INTERNATIONAL TECHNOLOGY, INC.
(Exact name of small business issuer as specified in its charter)

Colorado	**84-1509950**
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

2281 Guenette, Ville Saint-Laurent
Montreal, Quebec, Canada HR4 2E9
(Address of principal executive offices)

(514) 339-9355
(Issuer's telephone number)

(Former name, former address and former fiscal year, if changed since last report)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes [ ] No [X]

The number of shares outstanding of each of the issuer's classes of common equity as of June 30, 2006:
10,867,737 shares of common stock

Transitional Small Business Disclosure Format (check one): Yes [ ] No [X]

Index

MEDICAL INTERNATIONAL TECHNOLOGY, INC.
CONSOLIDATED BALANCE SHEET
JUNE 30, 2006
(UNAUDITED)

	June 30, 2006 (Unaudited)	September 30, 2005 (Audited)
Assets		
Current Assets		
Cash and cash equivalents	$ 145,986	$ 5,874
Accounts receivable	14,653	35,294
Inventories	148,339	97,423
Receivable from related parties	30,777	-
Research tax credit receivable	250,926	194,912
Prepaid expenses	15,649	-
Total Current Assets	606,330	333,503
Property and Equipment		
Tooling and machinery	225,175	204,048
Furniture and office equipment	60,816	59,372
Leasehold improvements	22,163	22,163
	308,154	285,583
Less accumulated depreciation	(162,075)	(158,293)
	146,079	127,290
Other Assets		
Intangible assets subject to amortization		
Patents (net accumulated amortization of $720, $601)	1,737	1,797
	1,737	1,797
Total Assets	$ 754,146	$ 462,590
Liabilities and Stockholders' (Deficit)		
Current Liabilities		
Unearned income	$ 65,352	$ 116,537
Accounts payable	167,476	608,444
Accounts payable – related parties	68,489	-
Accrued expenses	15,978	-
Taxes payable	8,943	-
Loans payable – related parties	323,325	361,698
Current portion of long-term debt	3,112	16,484
Total Current Liabilities	627,754	1,103,163
Long-term debt	-	-
Total Liabilities	627,754	1,103,163
Stockholders' Equity (Deficiency)		
Preferred stock, $0.0001 par valued; 3,000,000 shares authorized; none issued and outstanding as of June 30, 2006		
Common stock, $0.0001 par value; 100,000,000 shares authorized; 10,867,737 shares issued and outstanding as of June 30, 2006	1,086	474
Additional paid-in capital	5,905,080	3,920,512
Deficit	(5,763,916)	(4,525,846)
Accumulated other comprehensive loss	(15,858)	(35,713)
Total Stockholders' Equity (Deficit)	126,392	(640,573)
Total Liabilities and Stockholders' (Deficit)	$ 754,146	$ 462,590

The accompanying notes are an integral part of these consolidated financial statements.

MEDICAL INTERNATIONAL TECHNOLOGY, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)

	For the Three-Months Ended June 30,		For the Nine-Months Ended June 30,	
	2006	**2005**	**2006**	**2005**
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Sales	$ 99,330	$ 38,189	$ 192,574	$ 235,388
Cost of sales	48,285	17,334	101,813	121,190
Gross profit	51,048	20,855	90,761	114,198
Research and development costs	60,657	21,112	256,202	173,306
Selling, general, and administrative expenses	85,501	110,804	922,704	219,538
	146,158	131,916	1,178,906	392,844
Net loss before consulting fees	(95,110)	(111,061)	(1,088,145)	(278,646)
Consulting fees (non-cash)	(4,000)	(43,200)	(126,600)	(81,200)
Net loss from operations	(99,110)	(154,261)	(1,214,745)	(359,846)
Other Income (Expense)				
Interest income	-	-	688	11
Interest expense	(5,873)	(9,349)	(24,013)	(40,740)
Net Loss	$ (104,983)	$ (163,610)	$ (1,238,070)	$ (400,575)
Basic and diluted weighted average shares outstanding	7,806,081	4,621,311	7,806,081	4,621,311
Basic and diluted (loss) per share	$ (0.013)	$ (0.035)	$ (0.159)	$ (0.087)

The accompanying notes are an integral part of these consolidated financial statements.

MEDICAL INTERNATIONAL TECHNOLOGY, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)

	For the Nine-Months Ended June 30, 2006 (Unaudited)	June 30, 2005 (Unaudited)
Cash Flows from Operating Activities		
Net Loss	$ (1,238,070)	$ (400,575)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization expense	33,760	30,174
Common stock issued for consulting and legal services	237,176	81,200
Common stock for debt	241,999	-
Accrued interest expenses on indebtedness	-	9,791
Decrease in accounts receivable	20,641	-
Increase in receivable from taxing authorities	(56,014)	(143,976)
(Increase) in inventories	(50,916)	(6,186)
(Increase) in prepaid expenses	(15,649)	(10,642)
(Decrease) in unearned income	(51,185)	13,405
Increase (Decrease) in accounts payable and accrued expenses	(372,479)	227,300
Net Cash Used In Operating Activities	(1,250,737)	(199,509)
Cash Flows from Investing Activities		
Equipment acquisition	(22,630)	-
Net cash provided (used in) investing activities	(22,630)	-
Cash Flows from Financing Activities		
Advances from loans	-	89,752
Gross proceeds from private offerings	1,506,005	-
Advances (repayments) from related parties	(38,373)	126,505
Principal reduction on small business loan	(13,372)	(11,846)
Net cash provided by Financing Activities	1,454,260	204,411
Effect of exchange rates on cash	(40,781)	(11,173)
Net Increase (Decrease) in Cash and Cash Equivalents	140,112	(6,271)
Beginning Balance – Cash and Cash Equivalents	5,874	6,863
Ending Balance – Cash and Cash Equivalents	$ 145,986	$ 592
Supplemental Information:		
Cash Paid For:		
Interest Expenses	$ 24,013	$ 40,740
Income Taxes	$ -	$ -

The accompanying notes are an integral part of these consolidated financial statements.

MEDICAL INTERNATIONAL TECHNOLOGY, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

	Nine-Months Ended June 30, 2006	Nine Months Ended June 30, 2005
Net loss	$ (1,238,070)	$ (400,575)
Other comprehensive income (loss)		
Foreign currency translation adjustment	19,855	(11,173)
Net comprehensive loss	$ (1,218,215)	$ (411,748)

The accompanying notes are an integral part of these consolidated financial statements.

MEDICAL INTERNATIONAL TECHNOLOGY, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDER'S DEFICIT

	Common Stock Shares	Common Stock Amount	Additional Paid-In Capital	Deficit
Balance – September 30, 2004	4,583,301	$ 458	$ 3,825,917	$ (3,791,368)
Shares issued for debts	-	-	-	-
Shares issued for services	161,124	16	94,595	-
Net loss for the year ended September 30, 2005	-	-	-	(734,478)
Balance – September 30, 2005	4,744,425	$ 474	$ 3,920,512	$ (4,525,846)
Shares issued for debts	930,707	93	241,906	-
Shares issued for services	718,605	72	237,104	-
Shares issued private placements	4,474,000	447	1,505,558	-
Net loss for the period ended June 30, 2006	-	-	-	(1,238,070)
Balance – June 30, 2006	10,867,737	$ 1,086	$ 5,905,080	$ (5,763,916)

The accompanying notes are an integral part of these consolidated financial statements.

Note 1 – Basis of Presentation

Interim Financial Statements

The accompanying unaudited consolidated financial statements are presented in accordance with the requirements for Form 10-QSB and Article 10 of Regulation S-X and Regulation S-B. Accordingly, they do not include all the disclosures normally required by generally accepted accounting principles. Reference should be made to the Medical International Technology, Inc. (the "Company") Form 10–KSB for the year ended September 30, 2005; and the Form 10-QSB for the quarter ended March 31, 2006, for additional disclosures including a summary of the Company's accounting policies, which have not significantly changed. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the year ended September 30, 2006.

Note 2 - Going Concern

Generally accepted accounting principles in the United States of America contemplate the continuation of the Company as going concern. However, the Company has reported a net liability position of $21,424 and has accumulated operation losses since inception of $5,763,916, which raises substantial doubt about the Company's ability to continue as a going concern. The continuation of the company is dependent upon the continuing financial support of creditors and stockholders and upon obtaining the capital requirements for the continuing operations of the Company. Management believes actions planned and presently being taken provides the opportunity for the Company to continue as a going concern.

Note 3 – Summary of Significant Accounting Policies

Principles of consolidation

The accompanying consolidated financial statements include the accounts and transactions of Medical International Technology, Inc. and its wholly owned subsidiary, Medical International Technologies (MIT Canada) Inc. Intercompany transactions and balances have been eliminated in consolidation.

Foreign Currency Translations

The Company operates out of its offices in Montreal, Canada and maintains its books and records in Canadian Dollars. The consolidated financial statements herein have been converted into U.S. Dollars. Balance sheet accounts are translated at exchange rates in effect at the end of the period and income statement accounts have been translated at average exchange rates for the period. Translation gains and losses are included as a separate component of stockholders' equity.

Allowance for Doubtful Accounts

The allowance for doubtful accounts on accounts receivable is charged to income in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectibility is determined to be permanently impaired. As of June 30, 2006, the Company did not establish any reserve for doubtful accounts.

Inventories

Inventories are stated at the lower of cost determined by the FIFO method and market.

Property and Equipment

The cost of property and equipment is depreciated over the estimated useful lives of the related assets, which range from 5 to 7 years. Depreciation is computed on the straight-line method for financial reporting purposes and on the declining balance method for income tax reporting purposes. Depreciation expense for the nine-months ended June 30, 2006 and 2005 were $33,760, and $30,174, respectively.

Intangible assets

Patents are being amortized over their respective remaining lives ranging from 9.5 years through 17 years.

Net Loss Per Share

The Company adopted the provisions of Statement of Financial Accounting Standards ("SFAS") No. 128, "Earnings Per Share" ("EPS") that established standards for the computation, presentation and disclosure of earnings per share, replacing the presentation of Primary EPS with a presentation of Basic EPS.

Issuances Involving Non-cash Consideration

All issuances of the Company's stock for non-cash consideration have been assigned a dollar amount equaling either the market value of the shares issued or the value of consideration received whichever is more readily determinable.

Cash and Cash Equivalents

For purpose of the statements of cash flows, the Company considers cash and cash equivalents to include all stable, highly liquid investments with maturities of three months or less.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Long-Lived Assets

In August 2001, SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets," was issued establishing new rules and clarifying implementation issues with SFAS No. 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed of, "by allowing a probability-weighted cash flow estimation approach to measure the impairment loss of a long-lived asset. The statement also established new standards for accounting for discontinued operations. Transactions that qualify for reporting in discontinued operations include the disposal of a component of an entity's operations that comprises operations and cash flow that can be clearly distinguished, operationally and for financial reporting purposes, from the rest of the entity. The Company has adopted this standard and its adoption had no significant effect on the Company's financial statements

Reclassification

Certain amounts in June 30, 2005 have been reclassified to conform to the June 30, 2006 presentation. Such reclassification had no effect on net income as previously reported.

Income Taxes

The Company accounts for its income taxes under the provisions of Statement of Financial Accounting Standards 109 ("SFAS 109"). The method of accounting for income taxes under SFAS 109 is an asset and liability method. The asset and liability method requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of temporary differences between tax bases and financial reporting bases of other assets and liabilities.

Fair Value of Financial Instruments

Pursuant to SFAS No. 107, "Disclosures About Fair Value of Financial Instruments", the Company is required to estimate the fair value of all financial instruments included on its balance sheet as of June 30, 2006. The Company considers the carrying value of such amounts in the financial statements to approximate their face value.

Revenue Recognition

The Company recognizes revenue when the related product is shipped to the respective customer and ultimate collection is reasonably assured.

Note 4 - Intangible Assets

Amortization expense for the nine-months ended June 30, 2006 and 2005 were $180, and $174, respectively.

Note 5 - Stock Activity

On November 17, 2005, Shareholders, at a Special Shareholders' Meeting, approved a 1 for 10 reverse split of the Company's issued and outstanding stock. On November 21, 2005, subsequent to the reverse-split the Company was issued a new trading symbol. The new trading symbol is MDLH.

On November 30, 2005 the Company issued 520,000 post-reverse split restricted common shares at a price of $0.25 per share to Idee International R & D Inc., a company owned as to 100% by Karim Menassa for a debt conversion of $130,000.

On November 30, 2005 the Company issued 128,000 post-reverse split restricted common shares at a price of $0.25 per share to Karim Menassa, a Director and Officer of the Company for a debt conversion of $32,000.

On November 30, 2005 the Company issued 52,000 post split restricted common shares at a price of $0.25 per share to Technopro M.S. (2999226 Canada Inc.), for a debt conversion of $13,000.

On December 7, 2005, the Company completed two rounds of financing. The Units in these offerings were sold in exempt transactions under, Regulation "S" of the Securities Act of 1933 and are subject to Rule 144 of the Securities Act of 1933, as amended. The securities are restricted pursuant to Rule 144.

The first private placement consisted of 2,000,000 Units at a price of $0.25 per unit. Each unit consisted of one Series A Warrant for the purchase of 2,000,000 shares of the Company's common stock at an exercise price of $0.75 per share and one Series B Warrant for the purchase of 2,000,000 shares of the Company's common stock at an exercise price of $1.00 per share. Both the series A and series B warrants expire on October 27, 2007. The total amount raised from this placement was $500,000 of which the company was obligated to pay an 8% finder fee to Group InterCapital, Inc.,a consulting firm. Net proceeds to the company less the $40,000 finder fee were $460,000.The purchaser of this offering was a Canadian entity controlled by a daughter of the individual controlling the consulting firm.

The second private placement was for 1,224,000 Units at a price of $0.25 per Unit. Each unit of this second offering consisted of one Series A Warrant for the purchase of 1,224,000 shares of the Company's common stock at an exercise price of $0.75 per share and one Series B Warrant for the purchase of 1,224,000 shares of the Company's common stock at an exercise price of $1.00 per share. Both the series a and series B warrants expire on November 07, 2007. The total amount raised from this placement was $306,000 of which the company is obligated to pay an 8% finder fee to Group InterCapital, Inc., a consulting firm. Net proceeds to the company less the $24,480 finder fee were $281,520.

On December 20, 2005, the company sold in a private placement 1,000,000 Units at a price of $0.60 per Unit. Each unit sold in this offering includes one (1) Series A Warrant for a total of 1,000,000 shares of the Company's common stock at an exercise price of $0.75 per share The series A warrant expires on December 19, 2007. The total amount raised from this placement was $600,000 of which the company is obligated to pay a 9% finder fee to 9109-7923 Quebec Inc. Net proceeds to the company less the $54,000 finder fee were $546,000.

On February 27, 2006, the company issued 153,400 shares to 2849674 Canada Inc., a company owned as to 100% by Karim Menassa, a director and officer, for a debt conversion of $61,300.

Additionally, on February 27, 2006, the company issued 153,400 shares to 1065029 Canada Inc., a company owned as to 100% by Michel Bayouk, a director, for a debt conversion of $61,300.

On March 14, the company issued 25,000 unrestricted common shares to Geoffrey Armstrong, an employee for the exercise of options at a price of $0.40 per share pursuant to a Form S-8 registration filed December 27, 2005.

On March 24, the company issued 25,000 unrestricted common shares and on April 21, 2006 an additional 200,000 unrestricted common shares to Geoffrey Armstrong, an employee for the exercise of options at a price of $0.40 per share pursuant to the Form S-8 registration filed December 27, 2005

Note 6 - Related Party Transactions

On January 31st, 2002, Idee International R&D Inc., a company wholly owned by a majority shareholder of MIT, sold the company tooling, machinery, and other property for $146,331. the purchase price, in addition to an outstanding loan of approximately $99,825 due to Idee have been combined and are evidenced by a non-recourse promissory note bearing interest at an annual rate of 11.5%. Principal and accrued interest are payable on demand only after the company becomes profitable and the repayment of such loan does not impact the company's ability to operate and meet its normal obligation.

During the nine months, ended June 30, 2006 and during the year, ended September 30th, 2005 and 2004, the Company paid approximately zero $ in principal and $24 013 interest in this year and $26,954 and $24,923 in accrued interest on this loan, respectively. The balance of the loan as of September 30th, 2005 is the same as June 30, 2006 $297,132.

During the nine months period ended June 30, 2006 the Company repaid advances to another party, "SCANVIEW CORPORATION" a company controlled by a majority shareholder of MIT, Mr. Karim Menassa at 55% and Mr. Michel Bayouk at 10%; in the amount of $200,000, leaving a balance due as of June 30, 2006 of $10,468, and this balance does not bear any interest.

Note 7 – Commitments and contingencies

The Company leases its office under an operating lease that expires October 31, 2008. Future minimum annual lease commitments pertaining to the lease is $26,458.

Item 2. Management's Discussion and Analysis of Financial Condition and Plan of Operations

All statements that are included in this Quarterly Report, other than statements of historical fact, are forward looking statements. You can identify forward-looking statements by words such as “anticipate”, “believe” and similar expressions and statements regarding our business strategy, plans and objectives for future operations. Although management believes that the expectations reflected in these forward looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. The forward-looking statements in this filing involve known risks and uncertainties, which may cause our actual results in future periods to be materially different from any future performance suggested in this report. Such factors may include, but are not limited to: the ability to obtain additional funding further develop and market our products, changes in technology, market acceptance of our products, regulatory approval of our products in various markets, fluctuations in customer demand and commitments, pricing and competition, reliance upon subcontractors, together with such other factors as may be included in our Annual Report on Form 10-KSB

Financial Summary

Results of Operations for the Three-Months Ended June 30, 2006 and 2005

For the three-months ended June 30, 2006, the Company experienced a net loss of $104,983, primarily comprised of research and development expenses of $60,657 and selling, general and administrative expenses of $85,501. For the three-months ended June 30, 2005, the Company’s net loss was $163,610.

Selling, general and administrative expenses for the three-months ended June 30, 2006 were $146,158, compared to $131,916 for the three-months ended June 30, 2005.

For the three-months ended June 30, 2006, the Company’s sales were $99,330 resulting in an increase in sales of $61,141 compared to sales for the three-months ended June 30, 2005.

Gross profit for the three-months ended June 30, 2006 was $51,048 or 51% of sales as compared to 55% for the three-months ended June 30, 2005.

As of June 30, 2006, the Company maintains $50,699 as advances towards future sales pertaining to its non-exclusive distribution agreement with WLT Distributors Inc.

Liquidity and Capital Resources

For the nine months ended June 30, 2006 the Company’s cash position increased by $140,112. The Company spent $975,486 in its operations and received $1,454,260 from financing activities. Financing activities included gross proceeds from private offerings of $1,506,005; an amount repaid to related parties of $38,373; and principal reduction on small business loan of $13,372.

For the nine months ended June 30, 2005 the Company’s cash position decreased by $6,271. The Company spent $115,614 in its operations and received $204,411 from financing activities. Financing activities included advances from related parties of $126,505; advances from loans of $89,752; and the reduction of its principal amount of its small business loan of $11,846.

During this nine month period ended June 30, 2006, the company received investments of approximately $1,400,000 and has used most of those proceeds for the following expenses: $880,000 in operational expenses including payments to suppliers, sub-contractors, outside accountants and attorneys; Repayment of a $200,000 loan from Scanview; Fees to business consultants of $165,000 and finders fees of $118,000.

Medical International Technology, Inc. expects that revenues from existing and developing sales will not meet its liquidity requirements for the next 12 month period at its current level of operations. The company continues to rely on management to develop the business and work to develop sales. Management has and may continue to supplement cash flows from sales with additional equity and debt financing. Substantially, expanded operations are expected to require additional capital, either from a future offering of equity or the company pursuing other methods of financing, as appropriate.

Management Plan of Operations

Medical International Technology, Inc. ("MIT") is engaged in the business of research, development, marketing and sales of needle-free jet injector technology and products for humans and animals, for single and mass injections.

We continue to market our product in all available markets, seek regulatory approvals to expand those market opportunities and improve our products for application to new markets.

Medical International Technology, Inc. continues its efforts to secure additional funding to support and expand operations, develop and seek regulatory approvals for our products and market those products worldwide.

Medical International Technology, Inc. will continue to seek additional funding to expand operations and develop sales revenue to a volume sufficient to sustain operations

Product Development

Medical International Technologies has filed for FDA approval for its needle-free injector – the MED-JET, designed specifically for human mass inoculations. The MED-JET is capable of delivering many types of medications such as vaccines, insulin and other types of injectables. Its low-pressure technology offers an advantage to alternative high pressure systems that can cause blowbacks and expose medical workers and patients alike to microscopic traces of blood.

According to the International Sharps Injury Prevention Society (http://www.isips.org), it has been estimated that one out of every seven workers is accidentally stuck by a contaminated sharp point each and every year. The Center for Disease Control (CDC: http://www.cdc.gov/niosh/2000-108.html#5) estimates that there are 600,000 to 800,000 needle stick injuries per year in the U.S. alone, and many are not reported. More than 20 types of infectious agents have been transmitted through needlesticks, including hepatitis B and C, tuberculosis, syphilis, malaria, herpes, diphtheria, gonorrhea, typhus and Rocky Mountain spotted fever. The MED-JET will eliminate this risk to our health care professionals and create a safer workplace. Other advantages include its light weight (0.5 kg) and an excellent medication absorption rate. Additionally, the system has the ability to increase or decrease the volume and pressure of injection. This technology is unique to MIT's MED-JET MBX Injector. The system is designed to allow for the injection of up to 600 individuals an hour.

The approval process can be expensive and may take an extended period of time. There can be no assurance that this system will receive approval from the FDA or if approved gain broad acceptance by the medical community or individual patients.

On December 15, 2005, Medical International Technologies, Inc announced that it has received full certification granted under the International Organization for Standardization, as well as the Canadian Medical Device Conformity Assessment System, for devices to be licensed by HEALTH CANADA. These certifications allow MIT to market the Med-Jet Needle-Free Injector for human use in all countries other than the U.S., at this point. The Med-Jet injector has been submitted for FDA approval which, if accepted, will allow MIT to sell the Med-Jet in the United States, making it a truly worldwide system.

Now that MIT is able to sell its Med-Jet in all countries, other than the U.S., it is working to complete two FDA filings. The first of these will be for use of the Med-Jet for injecting anesthesia in a variety of situations. The second will be the Med-Jet-H, for mass vaccination in case of a pandemic, such as Avian Influenza, Polio, Tuberculosis, or Malaria .

We are currently responding to comments on our FDA application and must provide additional test information. We are planning for the completion of these additional tests over the next six months.

MIT is also pursuing increasing interest in its Agro-Jet needle-free injector. In Australia, we are awaiting approval of an injectable solution manufactured by a large pharmaceutical company which will be used in our injector systems. We expect that this approval will occur sometime in the second quarter of 2007.

On December 19, 2005 the Board of MIT adopted a resolution stating that " MIT will acquire all of the issued and outstanding shares of 9139-2449 Quebec Inc operating under the name "Scanview" for 2,500,000 restricted common shares of MIT". No shares have been issued and the final terms are pending acceptance by the shareholders of Scanview

Scanview is a portable ultrasound technology and manufacturing company based in Montreal, Quebec, Canada. ScanView was formed in 2003 to develop, manufacture and market different models of Real Time Ultrasound Scanners, for Animal and Human applications.

ScanView has a unique, portable and battery operated ultrasound diagnostic medical device, using a variety of probes for pathological and physiological evaluation of organs such as the heart, kidneys, liver, thyroid, uterus and ovaries. They serve equally well to detect kidney stones, diagnose pregnancy, visualize follicle development and carry out all other normal ultrasound diagnostic procedures.

ScanView is a private Canadian company owned by Karim Menassa, our CEO and Director, owning 55% of Scanview, Michel Bayouk, our CFO and Director, owning 10% of Scanview and three other unrelated shareholders.

The Acquisition of Scanview is pending an independent appraisal valuation of Scan View at the request of Medical International Technology. Based on the results of this valuation the acquisition of Scanview may proceed.

Going Concern

The Generally accepted accounting principles in the United States of America contemplate the continuation of the Company as going concern. However, the Company has reported a net liability position of $21,424 and has accumulated operation losses since inception of $5,763,916, which raises substantial doubt about the Company's ability to continue as a going concern. The continuation of the company is dependent upon the continuing financial support of creditors and stockholders and upon obtaining the capital requirements for the continuing operations of the Company. Management believes actions planned and presently being taken provides the opportunity for the Company to continue as a going concern.

We have limited capital with which to pursue our business plan. There can be no assurance that our future operations will be significant and profitable, or that we will have sufficient resources to meet our objectives. We may pursue either the option of debt or equity financing or a combination of both in order to raise sufficient capital in order to meet our financial requirements over the next twelve months and to fund our business plan. There is no assurance that we will be successful in raising additional funds.

Our future success will be dependent upon our ability to continue pursue market acceptance of our products; obtain regulatory approvals necessary to expand our markets and introduce or products to those markets through expanded sales operations.

Item 3. Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report. There were no changes in our internal control over financial reporting during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting

Part II. OTHER INFORMATION

Item 1. Legal Proceedings

None, for the period ending June 30, 2006.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

During the three month period ended June 30, 2006, no unregistered sales of equity securities occurred that had not been previously reported.

Stock Incentive Plan

The company has a stock incentive plan titled "Compensation" under which 750,000 common shares are authorized for issuance and have been registered, as amended on Form S-8 filed December 27, 2005. The plan relates to the Medical International Technology Stock Option Agreement dated October 1, 2005, with Geoffrey Armstrong for services, to Medical International Technology, Inc.

Under the "Compensation" plan, in the three month period ended June 30, 2006, no additional shares were issued.

As of June 30, 2006, a total of 500,000 common shares remain authorized for issuance under the "Compensation" plan.

Item 3. Defaults Upon Senior Securities

None

Item 4. Submission of Matters to a Vote of Security Holders

None during the three month period ended June 30, 2006.

Item 5. Other Information

None

Item 6. Exhibits and Reports on Form 8-K

Exhibits

Medical International Technology, Inc. includes herewith the following exhibits:

31.1 Certification of Principal Executive Officer (Rule 13a-14(a)/15(d)-14(a))
31.2 Certification of Principal Accounting Officer (Rule 13a-14(a)/15(d)-14(a))
32.1 Certification of Principal Executive Officer (18 U.S.C. 1350)
32.2 Certification of Principal Accounting Officer (18 U.S.C. 1350)

Reports on Form 8-K

None during the three month period ended June 30, 2006.

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Medical International Technology, Inc.

Date: August 21, 2006 By: /s/ Karim Menassa
Karim Menassa, President
Principal Executive Officer

Date: August 21, 2006 By: /s/ Michel Bayouk
Michel Bayouk, Secretary
Principal Accounting Officer